🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

27+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 27 recruiting trials for “Primary myelofibrosis

Phase 1RecruitingNCT07104799

Momelotinib During and After HCT in Myelofibrosis

👨‍⚕️ Gabriela Hobbs, MD, Massachusetts General Hospital📍 1 site📅 Started Feb 2026View details ↗
Phase 3RecruitingNCT07317700

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

👨‍⚕️ Xiao Zhijian, Doctor, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)📍 2 sites📅 Started Feb 2026View details ↗
Phase 1, PHASE2RecruitingNCT07128381

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

👨‍⚕️ Naveen Pemmaraju, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Jan 2026View details ↗
Phase 1, PHASE2RecruitingNCT06887803

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

👨‍⚕️ Michael Lahn, Dr, iOnctura📍 7 sites📅 Started Nov 2025View details ↗
Phase 1, PHASE2RecruitingNCT07281781

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

👨‍⚕️ Angela Flesichman, MD, PhD, Chao Family Comprehensive Cancer Center📍 1 site📅 Started Sep 2025View details ↗
Phase 2RecruitingNCT06770842

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

👨‍⚕️ Harinder Gill, MD, The University of Hong Kong📍 1 site📅 Started Mar 2025View details ↗
Phase 1, PHASE2RecruitingNCT06605586

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

👨‍⚕️ Peter te Boekhorst, Dr., Erasmus Medical Center📍 6 sites📅 Started Feb 2025View details ↗
Phase 1, PHASE2RecruitingNCT06773195

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

👨‍⚕️ Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center📍 9 sites📅 Started Jan 2025View details ↗
RecruitingNCT06533813

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

👨‍⚕️ TIZIANO BARBUI, MD, FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS📍 36 sites📅 Started Oct 2024View details ↗
Phase 1RecruitingNCT06313593

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

👨‍⚕️ Incyte Medical, Incyte Corporation📍 31 sites📅 Started Aug 2024View details ↗
Phase 3RecruitingNCT06479135

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

🏥 Kartos Therapeutics, Inc.📍 215 sites📅 Started Jun 2024View details ↗
Phase 2RecruitingNCT06457425

A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

👨‍⚕️ Zhijian Xiao, Doctor, Hematology Hospital, Chinese Academy of Medical Sciences📍 2 sites📅 Started May 2024View details ↗
Phase 2RecruitingNCT05980806

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

🏥 Karyopharm Therapeutics Inc📍 70 sites📅 Started Apr 2024View details ↗
Phase 1, PHASE2RecruitingNCT06122831

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 22 sites📅 Started Dec 2023View details ↗
RecruitingNCT06164561

18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.

👨‍⚕️ Jie Sun, MD,Ph.D, Zhejiang University📍 1 site📅 Started Nov 2023View details ↗
NARecruitingNCT07419178

A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept

🏥 Azienda Ospedaliero-Universitaria di Parma📍 1 site📅 Started Sep 2023View details ↗
Phase 1RecruitingNCT05535764

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis

👨‍⚕️ Sagar Patel, MD, Huntsman Cancer Institute📍 1 site📅 Started Aug 2023View details ↗
Phase 1, PHASE2RecruitingNCT05280509

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

🏥 Telios Pharma, Inc.📍 19 sites📅 Started Jun 2022View details ↗
Phase 1RecruitingNCT05371964

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

👨‍⚕️ Michelle Mudge-Riley, DO, Geron Corporation📍 8 sites📅 Started May 2022View details ↗
Phase 2RecruitingNCT05037760

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

👨‍⚕️ Study Director, Takeda📍 46 sites📅 Started Dec 2021View details ↗
Page 1 of 2Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →